Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Melanoma 25Uveal Melanoma 5Neoplasms 5Skin Neoplasms 3Carcinoma, Renal Cell 3Breast Neoplasms 3Prostatic Neoplasms 2Neoplasm Metastasis 2Lung Neoplasms 2Glioblastoma 2Eye Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Adenoma, Islet Cell 2Urologic Neoplasms 1Stomach Neoplasms 1Sarcoma 1Recurrence 1Rectal Neoplasms 1Pancreatic Neoplasms 1Osteosarcoma 1Neuroectodermal Tumors, Primitive, Peripheral 1Neoplasms by Site 1Myelodysplastic Syndromes 1Muscle Neoplasms 1Multiple Myeloma 1Leukemia, Plasma Cell 1Leukemia, Myeloid, Chronic-Phase 1Leukemia, Myeloid, Acute 1Leukemia, Myeloid, Accelerated Phase 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1

Interventions

Temozolomide 131Radiotherapy 87Bevacizumab 43Radiation 31Carmustine 29Magnetic Resonance Spectroscopy 22Irinotecan 22Erlotinib Hydrochloride 22Chemotherapy, Adjuvant 20Surgical Procedures, Operative 15O(6)-benzylguanine 15Carboplatin 14Radiotherapy, Intensity-Modulated 13Radiotherapy, Conformal 13sargramostim 12Sirolimus 9Imatinib Mesylate 9Filgrastim 9Drug Therapy 9temsirolimus 8Thalidomide 8Sorafenib 8Radiosurgery 8pembrolizumab 7motexafin gadolinium 7aldesleukin 7Vorinostat 7Procarbazine 7Gene Expression Profiling 7Gefitinib 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Gliosarcoma × montanide ISA 51 × Clear all
NCT02455557 2026-03-30

SurVaxM Vaccine Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma

Roswell Park Cancer Institute

Phase 2 Active not recruiting
66 enrolled 11 charts
CNSSarcoma

Glioblastoma, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡